For the treatment of locally advanced HNSCC, molecularly targeted agents, such as (the epidermal growth factor receptor (EGFR) inhibitor cetuximab) have shown modest success (Bonner et al., 2006). Here, EGFR is linked to head and neck squamous cell carcinoma.